Posts Tagged ‘Rhythm Pharmaceuticals’

Promise for a New Targeted Obesity Therapy Soon

August 9, 2019 — New data from Rhythm Pharmaceuticals this week tells us that a new, highly targeted obesity therapy may become available soon. The data come from two phase 3 studies of setmelanotide in rare cases genetic obesity. With these positive results in hand, Rhythm expects to file for FDA approval in late 2019 or early 2020. Thus, […]

Targeting Obesity: Win Some, Lose Some

July 22, 2016 — Targeting obesity with new treatments presents remarkable challenges. For evidence of this harsh reality, look at the sharply contrasting news this week for two potential new drugs: beloranib and setmelanotide. All work on beloranib was canceled by its developer, Zafgen. Almost simultaneously, Rhythm Pharmaceuticals published breakthrough results in the New England Journal of Medicine (NEJM) […]